How to Plan DTC Exclusions and Suppression Rules
A purpose-based exclusion register for DTC pharma media: minors, sensitive contexts, opt-outs, existing patients, and frequency, with owners and review dates.
The short answer
Exclusions decide who should not see a DTC pharma ad, where it should not appear, and when it should stop. They protect people, reduce waste, and lower regulatory and reputational risk. Most campaigns have exclusions. Few have a clear record of why each exists, who owns it, and when it was last reviewed.
A purpose-based exclusion register fixes that.
Four reasons to exclude
Every exclusion should serve at least one purpose:
- Protection. Avoid reaching people who should not receive the message, such as minors, or placing ads in contexts that could cause distress.
- Compliance. Honor opt-outs, privacy choices, and platform or legal restrictions.
- Relevance. Avoid messages that do not apply, such as acquisition ads to current patients.
- Efficiency. Stop spending on people who have seen enough.
If an exclusion does not serve any of these, question it. If a purpose has no exclusion, you may have a gap.
The exclusion register
| Rule | Purpose | Applies to | Owner | Review date |
|---|---|---|---|---|
| Age under 18 | Protection, compliance | All DTC | Media lead | Quarterly |
| Sensitive health content categories | Protection | Display, video | Brand safety lead | Quarterly |
| Opt-out and do-not-sell signals | Compliance | All data-driven | Privacy lead | Monthly |
| Current patients (acquisition flights) | Relevance | Acquisition only | Brand CRM lead | Per campaign |
| Frequency cap per household | Efficiency | CTV, video | Activation lead | Monthly |
Adding an owner and a review date is what turns a list into governance.
Sensitive contexts
Some contexts deserve exclusion regardless of brand safety scores. News about tragedies, content about serious illness for unrelated conditions, and content aimed at children are common examples. Brand safety tools help but are not perfect. Review placement reports regularly and add specific exclusions for problems you find.
Existing patients
Suppressing current patients from acquisition messages saves money and avoids confusing them. It requires a lawful and appropriate way to identify them, usually through the brand's own opt-in programs. Do not build suppression from data you are not permitted to use for that purpose. The distinction between consent, permission, and fitness for use matters here.
Frequency as an exclusion
Frequency caps are a form of suppression. Once someone has seen enough, stop showing the ad. See frequency caps in pharma programmatic for how to set and revisit them. For CTV, household frequency needs special handling; see CTV frequency management.
Test that exclusions work
Exclusions fail silently. A misconfigured segment or a partner that ignores a list will not raise an alert. Check placement and audience reports after launch to confirm excluded contexts and segments are not receiving impressions. Include this in your prelaunch QA.
Watch for over-exclusion
Too many exclusions can shrink reach and push delivery into lower-quality inventory. If reach collapses after adding rules, review whether each still serves its purpose.
Practical takeaway
Build the register before launch. For every exclusion, write the purpose, owner, and review date. Check delivery reports against it within the first week.
Sources
- FTC, Health Breach Notification Rule: The Basics for Business
- HHS, Use of Online Tracking Technologies by HIPAA Covered Entities
- Google Ads, Healthcare and medicines policy
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.